Cerulean to Host Third Quarter 2016 Conference Call on November 3

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Cerulean Pharma Inc. (NASDAQ: CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced it will provide an update on corporate activities for the third quarter 2016 on November 3.

Management will conduct a conference call at 4:30 p.m. ET that day to provide a business update and review the Company’s third quarter financial results. This call can be accessed by dialing (844) 831-3031 or (443) 637-1284 prior to the start of the call and referencing conference ID 7618037.

The conference call also will be webcast live over the Internet and can be accessed on the "Investors" section of the Cerulean website, www.ceruleanrx.com. The webcast will be archived on the Company's website for two weeks.

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial. For more information, please visit http://www.ceruleanrx.com/.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161027005788/en/

Cerulean Pharma Inc.
Nicole P. Jones, 781-209-6385
Director, Investor Relations and
Corporate Communications
[email protected]
or
Argot Partners
Susan Kim, 212-600-1902
Investor Relations
[email protected]

Source: Cerulean Pharma Inc.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Paychex (PAYX) Tops Q1 EPS by 2c
• On Holding AG (ONON) Stock: Market Doesn't Appreciate Brand's Potential, Says Analyst